A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.

Indeed, we found a positive trend (Pearson r = 0.54, P-value = 0.084) toward better TR2/CDH3 BAB efficacy in tumors showing a relatively higher percentage of cells co-expressing both markers ( Figure 5g ).

also in 6,779 other papers